Vision Expo East announces 2023 keynote speaker

Article

Jason Romero, a legally blind ultra-runner, will be giving the keynote address at the 2023 Vision Expo East meeting March 16-19 in New York City.

Vision Expo East has announced Jason Romero as the keynote speaker for 2023 annual conference held this year at the Javits Center in New York City next month from March 16-19. Romero is a legally blind ultra-runner.

“After losing his vision to a degenerative condition, [Romero] defied the odds to become an ultra-runner, crossing the United States on foot in only 60 days,” said Mitch Barkley, Vice President of Trade Shows and Meetings at The Vision Council. “[Romero’s] story of resilience and success underscores the life-changing value of sight and is an inspiration to us all. We are excited for attendees to hear from such an astounding and persevering speaker.”

This year’s Vision Expo East 2023 is expected to be the largest gathering of optical professionals in the United States in recent years, offering attendees content, products, and services changing the vision care industry. Romero’s address will add to the excitement.

“Losing my sight has had a profound impact on my life,” Romero said. “More than anyone else, I understand the value of vision care and I’m honored to have the opportunity to speak with so many innovators and leaders in the eye care community.”

“Challenge to Change” will feature remarks from Romero on Vision Expo’s main stage, The Bridge, on Saturday, March 18, at 3:30 p.m., where he will discuss his transformational journey from a successful executive to an unemployed, blind man to an elite-extreme athlete with more than ten world records.

“We are thrilled to welcome Jason Romero to the Vision Expo East education lineup,” said Fran Pennella, Vice President, Vision Expo at RX. “His inspirational story is just one example of the dynamic leaders and thought-provoking conversations that attendees will hear during this year’s Vision Expo East.”

With topics ranging from disease management and practice growth to lens innovation, eyewear trends, and more, expo attendees are invited to take advantage of the meeting’s CE offerings with over 300 hours of accredited education led by over 100 of the industry’s experts.

To learn more, visit the Vision Ed website. Vision Expo East, presented and organized by The Vision Council and RX (Reed Exhibitions).

Recent Videos
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.